![[Images/glp-1-at-25-adoption-restructures-american-healthcare-and-co.png]]

## The Take

**Consensus:** GLP-1s are a blockbuster pharma story—Novo and Lilly dominate, adoption grows, drug costs rise. Most investors treat this as a pharmaceutical sector bet: long Novo/Lilly, short bariatric surgery, watch for competition. The consensus focuses on drug pricing, pipeline competition, and manufacturer margins.

**Today:** The market is pricing GLP-1 as a pharma story. It's actually a macro story. 50-65 million American adults on GLP-1s by end of 2026 is not a pharmaceutical event—it's a restructuring of the American economy. The downstream effects cascade through healthcare, food, insurance, labor, and infrastructure in ways the market has not priced. The distribution disruption is equally significant: GLP-1s are the forcing function that breaks PBM opacity AND specialty pharmacy lock-in.

This is the most significant population-level health intervention since vaccines. Unlike statins or antihypertensives, GLP-1s produce visible, rapid changes in body composition. Unlike bariatric surgery, they're reversible, titratable, and now oral. The psychological and social effects compound the physiological ones.

The channel disruption is concrete: HCA dropped Wegovy/Zepbound coverage, directing employees to $200-$450 manufacturer D2C because they literally cannot determine if cash price beats "negotiated" price. Trump MFN deals cut prices 65-74%. The first oral GLP-1 approved Dec 2025 at $149/month via telehealth eliminates specialty handling requirements. Winners: digital pharmacy (Hims, Amazon, Cost Plus), pass-through PBMs (SmithRx, Capital Rx). Losers: specialty pharmacy margins, rebate-retention models.

The first-order effects are already visible: obesity prevalence dropped from 38% to 36% (Gallup 2023-2025), bariatric surgery volumes declining, Walmart reporting reduced food basket sizes, Constellation Brands citing GLP-1 as alcohol demand headwind. SELECT trial showed 20% CV event reduction with semaglutide; SURMOUNT trials showed 15-22% body weight reduction sustained.

The second-order effects are where the real restructuring occurs: CPG giants (PepsiCo, Coca-Cola, Mondelez) face structural demand decline; actuarial tables become obsolete; risk pool dynamics shift; airline seat economics change; apparel sizing distributions shift; body image norms reset. At the policy level, Medicare solvency improves if chronic disease costs bend, but states face short-term Medicaid budget pressure.

However, NBER research finds no cost offsets—non-GLP-1 spending INCREASES 9% year 1 and 30% by year 5. Cost-neutrality requires 70-80% price cuts to $3-4K/year. The persistence problem (14% at 3 years) means patients cycle on/off, potentially undermining chronic disease prevention benefits. And 3,063+ MDL lawsuits create headline risk.

**In 3-5 years:** GLP-1 adoption at 25% creates a demand shock that propagates through healthcare ($70B new drug spend, bending chronic disease cost curve), food/beverage (structural caloric demand decline), insurance (actuarial tables obsolete), labor (productivity gains, workforce reallocation), infrastructure (physical environment designed for obesity-era bodies), and culture (body norms, stigma, identity). The PBM model breaks—pass-through PBMs reach 10%+ market share, digital pharmacy captures oral GLP-1 distribution, and pricing transparency tools expose spread pricing. Winners: digital pharmacy, pass-through PBMs, GLP-1 adherence platforms, muscle preservation services. Losers: rebate-retention PBMs, bariatric surgery, CPAP, non-GLP-1 diabetes drugs, snack CPG, alcohol.

**How this evolved:**
- *2026-01-26:* **REBUILD** — Added NBER cost-offset research (no savings even at 5 years), McKinsey pharmacy cost growth data, GLP-1 prescription trend data (>7% of all prescriptions). Contrarian threats: persistence at 14% (HIGH), cost offsets not materializing (HIGH).
- *2026-01-11:* **PRESSURE TESTED** — Adversarial rebuild confirmed thesis with caveats. Added MDL lawsuit exposure (3,063 cases), insurance coverage pushback (HCA, BCBS, Medi-Cal), weight regain dynamics.
- *2026-01-07:* **MERGED** PBM Transparency/Channel Disruption thesis — unified insight: GLP-1s as forcing function for both macro-economic restructuring AND distribution channel disruption.
- *2025-12-27:* Extended GLP-1 adoption thesis to map first and second-order implications across healthcare, consumer, and societal domains.

---

## Bull Case

- [x] **GLP-1 adoption accelerating past 7% of all prescriptions** — 2.19M patients prescribed Jan 2019-Dec 2025; 70.7% fill rate; tirzepatide leading both AOM and ADM categories ([[Sources/Browser-History/2026-01-22-glp-1-ra-prescription-trends-january-2019-decembe]])
- [x] **Oral format eliminates specialty moat at $149/month** — FDA approved oral Wegovy Dec 2025; 16.6% weight loss; no cold chain, no injection training, standard mail-order economics; Goldman projects pills capture 24% of $22B global weight loss market by 2030 ([[novo-nordisks-weight-loss-pill-approved-by-fda]])
- [x] **Medicare coverage launches H2 2026 at $50/month** — BALANCE Model: Part D Jan 2027, Medicaid May 2026; Trump MFN cuts Ozempic $1,000→$350, Zepbound $1,086→$346 ([[2025-12-30_Trump-close-to-deal-to-allow-Medicare-coverage-of-weight-los]])
- [x] **Direct pricing beats PBM "negotiation"** — HCA directing employees to manufacturer D2C; cash beats commercial 47% of the time; JPMorgan lawsuit: CVS charged $6,229 vs $11.05 at Cost Plus (200x higher) ([[2025-12-23-jpmorgan-employees-claim-banking-giant-mismanaged]])
- [x] **Employer costs spiking, forcing channel disruption** — 79% of employers seeing increase in GLP-1 utilization; drug expenses up 20%+ in 2025; some insurers spent more on drugs in nine months than all of 2024 ([[2025-12-23-2026-employer-health-care-strategy-survey-executiv]])
- [x] **Consumer behavior shifts already visible** — Walmart CEO reports reduced basket sizes; Constellation Brands cites GLP-1 headwinds; Cornell research confirms changed food purchases; Gallup shows obesity 38%→36% ([[Sources/LLM-Chats/2026-01-06-glp1-adjacent-investment-opportunities]])
- [x] **Regulatory pressure building on PBMs** — Arkansas first-in-nation PBM pharmacy ownership ban; 6+ states pending; 39 AGs urged Congress; Executive Order 14221 with $5,500/day penalties ([[2025-12-23-arkansas-pbm-law-could-spur-lookalike-restrictions]])
- [x] **Meta-analysis validates efficacy** — 56 studies, 60,000+ patients: semaglutide/tirzepatide deliver >10% body weight loss, double older obesity drugs; SELECT trial shows 20% CV event reduction ([[2025-12-31-GLP-1 Research Tracker - Latest Obesity & Weight Loss Research]])

---

## Bear Case

- [x] **14% three-year persistence** — 86% of patients stop Wegovy within 3 years (HealthVerity); weight regain is 4x faster after GLP-1 discontinuation vs diet/exercise; if patients cycle on/off, chronic disease prevention benefits diminish ([[Sources/LLM-Chats/2026-01-22-glp1-cost-offset-research]])
- [x] **NBER: No cost offsets found** — Non-GLP-1 spending INCREASES 9% year 1, 30% year 5; drug costs dominate; no savings even 5 years post-initiation; cost-neutrality requires 70-80% price cut to $3-4K/year ([[Sources/Browser-History/2026-01-22-do-glp-1-medications-pay-for-themselves-nber]])
- [x] **3,063 MDL lawsuits and growing** — Doubled from 1,500 in Oct 2025; key allegations: gastroparesis, ileus (FDA-confirmed causal link), NAION vision loss (7.6x odds in diabetics per Harvard study), gallbladder complications ([[Sources/LLM-Chats/2026-01-22-glp1-cost-offset-research]])
- [x] **Insurance coverage pushback** — HCA dropped coverage; BCBS Michigan limiting; California Medi-Cal cutting reimbursement; employers can't determine if cash price beats "negotiated" price ([[Employers drop coverage for weight loss drugs as pharma's direct-to-consumer programs grow]])
- [x] **Muscle loss at scale** — 13.9% lean mass loss in STEP-1 trial (vs 26.3% fat loss); at 50M patients, even 20% with significant sarcopenia = 10M Americans with new frailty risk ([[Sources/LLM-Chats/2026-01-22-glp1-cost-offset-research]])
- [x] **Eli Lilly at 53x P/E** — vs pharmaceutical industry average 10x; market may have priced in adoption rates that won't materialize if persistence stays at 14% ([[Sources/LLM-Chats/2026-01-06-glp1-adjacent-investment-opportunities]])
- [ ] **RFK Jr. regulatory uncertainty** — Vowed to end "FDA's war" on peptides; unclear if helps (compounding access) or hurts (quality control); FDA/Lilly cracking down on 503A pharmacies
- [ ] **Highest ROI is for young/healthy, not sickest patients** — USC microsimulation shows best social returns from AOMs for BMI 30-39 with lower diabetes risk; generic entry not until 2032 extends high-cost period ([[2025-12-23-lifetime-social-returns-from-expanding-access-to-a]])
- [ ] **Medicaid patients may not access GLP-1s** — Colorectal screening 39% vs 56% commercial, diabetes control 52% vs 71%; 72M Medicaid patients underserved, creating bifurcated adoption where demand shock applies primarily to commercially insured ([[20aug25-robinhood-health-pitch-deck-c86df716]])
- [ ] **Trump revoked healthcare cost reduction models** — Biden October 2022 EO revoked; ACA expansion rolled back; federal hiring freeze at HHS; creates policy headwinds for GLP-1 Medicare coverage expansion and government-facilitated price reduction ([[2025-12-23-trumps-initial-orders-reverse-biden-on-health-care]])

**What would have to be true for you to be wrong?** The persistence problem would need to remain at or below 20% through 2028, meaning the vast majority of patients cycle off within three years and regain weight, undermining the chronic disease prevention thesis. Simultaneously, the cost offsets that CMS is betting on would fail to materialize within 5 years, making GLP-1s a net cost increase without population health benefit. If PBMs successfully place oral GLP-1s in specialty tiers with rebate gates, and Novo/Lilly sign exclusive distribution with CVS Specialty or Express Scripts, the channel disruption thesis also fails. The combination of persistent cycling, no cost savings, and PBM entrenchment would reduce GLP-1s from a macro restructuring event to just another expensive pharmaceutical that primarily enriches manufacturers.

---

## Timeline

**Now → 2026:** GLP-1 adoption crossing 20% US adult population. Oral Wegovy launched at $149-$299/month via D2C. Medicare coverage begins H2 2026 (BALANCE Model). More employers dropping PBM coverage for D2C (watch Fortune 500 after HCA). 3+ additional states pursue Arkansas-style PBM restrictions. >50% of GLP-1 starts predicted to be cash pay DTC. Watch for: digital pharmacy share of oral scripts; PBM tier placement decisions for oral format.

**2027 → 2028:** Inflection point for cost savings evidence—CMS needs 3-5 years of data. First measurable reductions in diabetes/CVD claims in GLP-1 cohorts. Food/beverage industry reports structural volume decline. Pass-through PBM market share reaches 10%+. Actuarial tables begin updating. Big 3 PBM earnings show pharmacy services margin compression. Critical question: does persistence improve with oral format and lower cost?

**2029+:** If cost curve bends, Medicare solvency improves and political support solidifies. If not, program could be cut before savings visible. CPG/restaurant industry fully repriced for reduced caloric demand. Bariatric surgery volumes stabilized at 50%+ below peak. Infrastructure accommodations (airline seats, stadiums) begin adjusting. New equilibrium: GLP-1 as chronic maintenance therapy integrated into primary care.

---

## Startup Opportunities

**1. PBM Contract Audit Platform**
- Why this follows: Once CMS enforces MRF data, $0 acquisition cost for NDC-level pricing. Every overpayment identifiable. $900M+ compliance TAM.
- Wedge: Sell to benefits consultants (60% influence PBM selection). Reference-based pricing comparison.
- Risk: CVS acquiring audit capabilities (Codoxo $35M, 80M+ lives). Big 3 may bundle as defensive.

**2. GLP-1-First Digital Pharmacy**
- Why this follows: Oral format eliminates cold chain, enables $149/month mail-order with telehealth. Novo's oral launch via "select telehealth providers" signals manufacturer openness.
- Wedge: Full-stack: prescribing + dispensing + monitoring + behavior change. Hims already acquired peptide facility + lab testing.
- Risk: PBM retaliation, need manufacturer relationships. Telehealth players (Hims, Ro) may dominate.

**3. Employer GLP-1 Carve-Out**
- Why this follows: Employers facing 20%+ drug cost increases need alternatives to PBM pass-through. Cigna's 10-20% savings proves demand.
- Wedge: Oral simplifies logistics; PMPM guarantees, level-funded insurance, GLP-1 utilization prediction.
- Risk: Scale economics difficult; need manufacturer deals. *Portfolio validation:* WriteWise building specialty pharmacy carve-out for 500-5K employers.

**4. GLP-1 Adherence Platform**
- Why this follows: 14% 3-year persistence = massive retention problem. Behavior change + monitoring + side effect management.
- Wedge: Partner with payers who save $20K+ per year if patient stays adherent vs cycling on/off.
- Risk: Telehealth players bundle adherence into prescribing platforms.

**5. Muscle Preservation Services**
- Why this follows: GLP-1s cause lean mass loss. If 50M Americans lose muscle, sarcopenia becomes next epidemic. 13.9% lean mass loss in STEP-1.
- Wedge: PT + nutrition + resistance training bundled with GLP-1 prescribing. Counter sarcopenia.
- Risk: Fragmented market, low tech defensibility.

**6. Medicare GLP-1 Navigation**
- Why this follows: BALANCE Model has complex eligibility; voluntary state participation creates fragmentation. Jan 2027 Part D launch = greenfield.
- Wedge: Prior auth, eligibility verification, appeals automation.
- Risk: CMS may simplify; PBMs may bundle.

---

## Watch For

**If RIGHT:**
- GLP-1 adoption crosses 20% US adult population by end of 2026
- Major CPG company reports structural volume decline citing GLP-1
- Health insurer reports measurable reduction in diabetes/CVD claims in GLP-1 cohort
- More employers drop GLP-1 coverage for D2C (watch Fortune 500)
- 3+ additional states pass Arkansas-style PBM restrictions by end of 2026
- Oral GLP-1s placed in mail-order tier, not specialty tier, by major PBMs
- Digital pharmacy share of oral scripts exceeds 10% within 12 months
- Pass-through PBM market share reaches 10%+ (currently 5-8%)
- Big 3 PBM earnings show pharmacy services margin compression

**If WRONG:**
- 3-year persistence stays below 20% (currently 14%) — weight regain dominates
- Downstream healthcare savings fail to materialize within 5 years (NBER confirmed)
- Side effects (muscle loss, gastroparesis, gallbladder) trigger regulatory restrictions
- MDL lawsuits result in major settlements or FDA restrictions
- Oral formulations fail to achieve injectable efficacy, slowing consumer adoption
- Trump MFN deals legally challenged and blocked
- Major PBMs place oral GLP-1s in specialty tier with rebate gates
- Novo/Lilly sign exclusive distribution with CVS Specialty or Express Scripts
- Digital pharmacy share remains <5% after 18 months

---

## Evidence

| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2026-01-26 | [[Sources/Browser-History/2026-01-22-glp-1-ra-prescription-trends-january-2019-decembe]] | Research | "GLP-1s now >7% of all prescriptions (Dec 2025); 2.19M patients prescribed Jan 2019-Dec 2025; 70.7% fill rate within 60 days" |
| 2026-01-26 | [[Sources/Browser-History/2026-01-22-do-glp-1-medications-pay-for-themselves-nber]] | Research (COUNTER) | "NBER: No cost offsets found—non-GLP-1 spending INCREASES 9% year 1, 30% year 5; drug costs dominate" |
| 2026-01-26 | [[Sources/LLM-Chats/2026-01-22-glp1-cost-offset-research]] | Research | "Consensus: GLP-1s do NOT pay for themselves. Cost-neutrality requires 70-80% price cut to $3-4K/yr" |
| 2026-01-26 | [[Sources/Browser-History/2026-01-22-healthcare-trends-for-2026-and-beyond-mckinsey]] | Research | "McKinsey: Pharmacy costs grew 9% annually 2021-2024, driven by GLP-1s; US gross drug expenditure expected to reach $990B by 2029" |
| 2026-01-26 | [[Sources/Granola/Charles Yang (Renaissance) __ Sean _ Emre (Virtue)]] | Expert | "Renaissance Reinsurance: $600M+ healthcare PA spend; seeing GLP-1 cost pressure across employer books" |
| 2026-01-26 | [[Sources/LLM-Chats/2026-01-06-glp1-adjacent-investment-opportunities]] | Research | "PMPM costs $1.43 (2019) → $24.59 (2024) = 77% CAGR; 35% of US food/bev sales from GLP-1 households by 2030" |
| 2026-01-26 | [[Sources/Browser-History/2026-01-13-use-of-pricing-information-published-under-the-tra]] | Policy | "CMS: Machine-readable files with in-network rates required since July 2022; third-party developers enabled" |
| 2026-01-26 | [[Sources/Browser-History/2026-01-13-federal-register-request-for-information-regardin]] | Policy | "Treasury/Labor/HHS RFI on prescription drug machine-readable file disclosure" |
| 2026-01-26 | [[Sources/Market-Research-PDFs/insito-health-b35e58ce]] | Company | "Insito Health: Medfinder AI—16K+ patients, $2.17M run rate, Lilly enterprise customer. $97B TAM" |
| 2026-01-26 | [[Sources/News/2026-01-02_The-GLP-1-Pricing-Revolution-How-Novo-Nordisk-and-Eli-Lilly]] | News | "GLP-1 pricing revolution: Novo vs Lilly price competition intensifying; DTC channels bypassing PBMs" |
| 2026-01-26 | [[Sources/News/2026-01-05_Novo-Nordisk-launches-first-GLP-1-pill-for-obesity-but-Lilly]] | News | "Novo launches oral Wegovy at $149-$299/month; eliminates cold chain and specialty handling" |
| 2026-01-26 | [[Sources/Browser-History/2026-01-02-rybelsus-mounjaro-wegovy-indias-weight-loss-drug-b]] | News | "India GLP-1 market explosion: 6x growth; patent expirations Mar 2026 enable generic competition" |
| 2026-01-12 | [[Sources/Browser-History/2026-01-12-2026-healthcare-predictions-part-2-out-of-pocket]] | Research | "10% of Wegovy, 30% of Zepbound is cash pay. >50% of GLP-1 starts in 2026 predicted cash pay DTC" |
| 2026-01-09 | [[Sources/News/2026-01-09/alveus-launches-with-160m-to-advance-maritide-like-obesity-drug]] | News | "Alveus raises $160M for obesity drugs; continued market expansion beyond Lilly/Novo duopoly" |
| 2026-01-06 | [[2026-01-06-aom_weighing-the-evidencepdf]] | Research | "RGA actuarial model: GLP-1s reduce US mortality 3.5% by 2045; 12% obesity prevalence reduction; anti-selection risk" |
| 2026-01-05 | [[Sources/News/2026-01-05_Novo-Nordisk-launches-first-GLP-1-pill-for-obesity-but-Lilly]] | News | "Oral Wegovy launched Jan 5, 2026 at $149-299/month; available at 70,000+ pharmacies" |
| 2026-01-05 | [[2026-01-03-town-hall-ventures-2026-predictions]] | News | "Town Hall 2026 predictions on GLP-1 market evolution" |
| 2026-01-05 | [[2026-01-01-8-predictions-for-healthcare-2026]] | News | "Healthcare 2026 predictions including GLP-1 adoption" |
| 2026-01-05 | [[glp-1-health-plans-weight-management-market]] | Research | "GLP-1 health plans and weight management market analysis" |
| 2026-01-02 | [[the-new-price-transparency-stack-and-the-very-inve]] | Research | "New transparency rule creates $900M+ compliance TAM" |
| 2026-01-02 | [[trump-to-test-most-favored-nation-pricing-for-medicare-shionogi-pays-25b-for-als]] | News | "Trump proposes Medicare pilot programs - $27B savings forecast" |
| 2026-01-01 | [[Rybelsus-Mounjaro-Wegovy-Indias-weight-loss-drug-boom-and-th]] | News | "India GLP-1 market 6x growth; semaglutide patent expires March 2026" |
| 2025-12-31 | [[2-Companies-Poised-to-Capitalize-on-the-Rise-of-GLP-1-Weight]] | News | "Morningstar analysis of Novo/Lilly GLP-1 positioning" |
| 2025-12-31 | [[2025-12-31_Lilly-and-Novo-Cut-GLP-1-Prices-as-Pill-Approvals-Expand-Acc]] | News | "Lilly and Novo strategically cutting GLP-1 prices to expand market access" |
| 2025-12-31 | [[2025-12-31-GLP-1 Research Tracker - Latest Obesity & Weight Loss Research]] | Research | "Meta-analysis: 56 studies, 60,000+ patients. Semaglutide/tirzepatide deliver >10% body weight loss" |
| 2025-12-30 | [[2025-12-30_Zepbound-tops-Wegovy-for-weight-loss-in-first-head-to-head-s]] | Research | "Zepbound beats Wegovy in head-to-head study. Competition intensifying" |
| 2025-12-30 | [[2025-12-30_Trump-close-to-deal-to-allow-Medicare-coverage-of-weight-los]] | Policy | "Trump administration close to deal allowing Medicare coverage of weight loss drugs" |
| 2025-12-30 | [[2025-12-30_Eli-Lilly-Novo-waging-price-wars-as-obesity-drug-market-heat]] | News | "Eli Lilly and Novo Nordisk escalating price competition in China's obesity drug market" |
| 2025-12-30 | [[2025-12-30_With-the-Wegovy-pill-Novo-Nordisk-undercuts-Eli-Lilly-in-dir]] | News | "Novo oral Wegovy undercuts Lilly in DTC market" |
| 2025-12-30 | [[2025-12-30_Certain-obesity-drugs-will-cost-as-little-as-149-and-Medicar]] | Policy | "Medicare coverage at $149, White House price negotiation" |
| 2025-12-30 | [[2025-12-30_Lilly-vs-Novo-Nordisk-Why-2026-Could-Redefine-the-Obesity-Dr]] | News | "2026 positioned as inflection year for obesity drug market competitive dynamics" |
| 2025-12-30 | [[2025-12-30-The 5 most important ideas for 2026 - by Ashwin Sharma, MD]] | Research | "TRIUMPH-4 validates obesity market segmentation: consumer/aesthetics vs medical" |
| 2025-12-30 | [[noom-pivots-to-longevity-new-program-combines-microdose-glp-1s-with-at-home-biom]] | News | "Noom pivots to longevity with microdose GLP-1 + biomarker testing at $149/month" |
| 2025-12-29 | [[novo-nordisks-weight-loss-pill-approved-by-fda]] | News | "FDA approved oral Wegovy Dec 22, 2025. 14% weight loss at 25mg dose. $100B+ combined market by 2030" |
| 2025-12-29 | [[noom-launches-glp-1-microdosing-for-longevity]] | News | "Noom launches GLP-1 microdosing for longevity—signals expansion beyond obesity" |
| 2025-12-29 | [[2025-12-29_Cancer-Benefits-and-Risks-From-Ozempic-Wegovy-and-Other-Weig]] | Research | "Memorial Sloan Kettering explores cancer implications of GLP-1s" |
| 2025-12-29 | [[2025-12-29_Medicare-to-Cover-Obesity-Drugs-Under-Trump-Deal-for-as-Litt]] | Policy | "Medicare coverage at $50/month—major price accessibility inflection point" |
| 2025-12-29 | [[2025-12-29-The trend of unproven peptides is spreading through influencers and RFK Jr. alli]] | News | "Peptide trend spreading through influencers. RFK Jr. vowed to end FDA's war on peptides" |
| 2025-12-29 | [[2025-12-23-2025-preview-what-does-the-year-ahead-hold-for-pha]] | Research | "Investors expect more deal making...strong drivers of growth in the form of the GLP-1s" |
| 2025-12-29 | [[2025-12-23-2026-employer-health-care-strategy-survey-executiv]] | Research | "79% of employers seeing increase in obesity medication utilization. 90% require prior auth" |
| 2025-12-29 | [[2025-12-23-astrazeneca-abandons-neuroscience-prioritizes-weig]] | News | "AstraZeneca abandons neuroscience to prioritize weight management" |
| 2025-12-29 | [[2025-12-23-cms-announces-manufacturer-participation-in-second]] | Policy | "Ozempic, Rybelsus, Wegovy included in second cycle of Medicare Drug Price Negotiation" |
| 2025-12-29 | [[2025-12-21-health-insurer-prescription-costs-rise-20-glp-1s-c]] | News | "Drug expenses up more than 20% in 2025. Some insurers spent more in nine months than all of 2024" |
| 2025-12-24 | [[2025-12-24-CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promot]] | Policy | "BALANCE Model: Part D Jan 2027, Medicaid May 2026. $50/month patient cost" |
| 2025-12-23 | [[2025-12-23-glp-1s-cancer-care-are-driving-higher-employer-hea]] | News | "Employers expect health care costs to spike by median 9% next year; survey of 121 employers covering 11.6M people" |
| 2025-12-23 | [[2025-12-23-healthcare-price-transparency-research-findings-an]] | Research | "MA prices <50% of commercial. Cash beats commercial 47%" |
| 2025-12-23 | [[2025-12-23-hims-hers-to-offer-at-home-blood-draws-lean-into]] | Company | "Hims acquires Trybe Labs + peptide facility. Peptide innovation at forefront" |
| 2025-12-22 | [[2025-12-22-fda-approves-first-glp-1-pill-for-obesity-from-weg]] | Policy | "First oral GLP-1 approved. $149/month via telehealth. Goldman: 24% pill share by 2030" |
| 2025-12-18 | [[Employers drop coverage for weight loss drugs as pharma's direct-to-consumer programs grow]] | Research | "HCA dropped GLP-1 for D2C. Manufacturer discounts less expensive than negotiated plan price" |
| 2025-12-17 | [[Codoxo's Oversubscribed Series C Led by CVS Health Ventures to Revolutionize Payment Integrity for America's Largest Health Plans]] | Company | "CVS Ventures led $35M. 80M+ lives. Big 3 building transparency capability" |
| 2025-12-15 | [[Virtue - Internal Team Sync-2025-12-15_10-00-52]] | Granola | "Retatrutide Phase 3 data showing 30% weight loss over one year—population-scale utilization inevitable" |
| 2025-12-29 | [[writewise---external-investment-memo-fa648167f8db45a6b83833a-6f018655]] | Portfolio | "WriteWise: Specialty carve-out for SMB employers. PMPM guarantees + GLP-1 prediction" |
| 2025-11-06 | [[2025-12-23-fact-sheet-president-donald-j-trump-announces-majo]] | Policy | "Trump MFN: Ozempic $1,000→$350. Zepbound $1,086→$346. Medicare $245, $50 copay" |
| 2025-05-30 | [[2025-12-23-analysts-cignas-glp-1-program-may-help-employers-s]] | Research | "Cigna caps at $200/month. 10-20% employer savings" |
| 2025-04-21 | [[2025-12-23-arkansas-pbm-law-could-spur-lookalike-restrictions]] | Policy | "Arkansas first-in-nation PBM pharmacy ownership ban. 6+ states pending. 39 AGs urged Congress" |
| 2025-12-23 | [[2025-12-23-eli-lilly-sues-four-telehealth-compounding-glp-1-c]] | Company | "Lilly suing 4 telehealth compounders. Legal pressure intensifying" |
| 2025-07 | [[2025-12-23-how-health-care-remade-the-us-economy]] | News | "Healthcare spending exceeds groceries and housing as share of US household expenditures; GLP-1s expected to reduce obesity-related chronic conditions" |
| 2025-03 | [[2025-12-23-lifetime-social-returns-from-expanding-access-to-a]] | Research | "USC microsimulation: expanded AOM access generates >13% annual social return; life expectancy rises up to 1.8 years; $260B spent annually treating obesity; generic GLP-1 entry projected 2032" |
| 2025-05 | [[Rabi Alam and Emre Karatas-2025-05-14_09-59-08]] | Operator | "Counter: shadow adjudicator optimizing PBM contract variations; ROI from 3.5x to 7-8x; $765K ARR, 60K lives, 83% gross margins, $14M post-money" |
| 2026-01-08 | [[2026-01-08-writewise]] | News | "WriteWise manages pharmacy spend through PMPM guarantees, works with 20+ PBMs; stop-loss pharmacy guarantees respond to GLP-1-driven cost escalation" |
| 2025-12 | [[2025-12-30_Eli-Lilly-Novo-waging-price-wars-as-obesity-drug-market-heat]] | News | "Eli Lilly and Novo Nordisk waging price wars in China's obesity drug market — competitive dynamics intensifying globally" |
| 2025-12 | [[12-mavrx-platform-saas-pbm-pricing-150a0269]] | Research | "MavRx/WriteWise SaaS platform for PBMs: predictive PMPM guarantees, NDC-level cost projections, PBM auction/bidding; $3,600-$10,000/month + $2.25-$6.00 PMPM" |
| 2025-12 | [[Virtue - Internal Team Sync-2025-12-15_10-00-52]] | Operator | "Retatrutide Phase 3: 30% weight loss over one year; 'population-scale utilization inevitable as costs drop, efficacy improves'" |
| 2025-12 | [[Claude-AI pharmacy operations automation for health systems]] | Analysis | "PBM profit pool shift: rebates collapsed from 47% (2012) to 17% (2025); specialty pharmacy grew to 37% of profit pool" |
| 2025-12 | [[2025-12-29_White-House-strikes-deals-for-lower-prices-on-obesity-drugs]] | News | "White House negotiating lower obesity drug prices with Novo and Lilly — government intervention to expand GLP-1 access via Medicare" |
| 2025-07 | [[ABT-2025-Q2]] | Operator | "Abbott building 'best-in-class portfolio of biosimilars' with 10 submissions beginning 2026 including 'access to GLP-1s' in emerging markets" |
| 2025-06 | [[Rabi Alam and Emre Karatas]] | Operator | "Counter Health: ProAct PBM partnership sees Counter as 'innovation differentiator for RFPs'; Cigna partnership advancing; 33-35% pharmacy care navigation market capture potential" |
| 2024-01 | [[nomi-health-investor-deck-01182024-24193fe9]] | Research | "Nomi Health transparent pass-through PBM: 'up to 30-50% savings on eligible drug spend', 99% client retention on 500K lives" |
| 2025-12 | [[Claude-Startup opportunities from report analysis]] | Analysis | "Nephron: PBMs 'in peril' facing regulatory risk, MFP implementation, 340B changes; 'unbundling of PBM services continues'" |
| 2025-08 | [[2025-12-23-2026-employer-health-care-strategy-survey-executiv]] | Research | "79% of employers seeing increased GLP-1 utilization; 90% require PA; pharmacy costs projected 11-12% increase; 24% of health care dollars went to pharmacy (2024)" |
| 2025-08 | [[2025-12-23-2026-employer-health-care-strategy-survey-executiv]] | Research | "Employers predict 9% cost trend (7.6% after plan changes); calling for 'macro-level overhaul of pharmacy supply chain'; exploring non-traditional PBM models" |
| 2026-01 | [[insmeds-ginormous-lung-drug-sales-jjs-us-pricing-deal]] | News | "J&J agreed to MFN pricing: government online drug purchasing channel, US prices comparable to foreign countries; $55B US manufacturing commitment" |
| 2026-01 | [[insmeds-ginormous-lung-drug-sales-jjs-us-pricing-deal]] | News | "Lilly Zepbound + Taltz combo: 32% of psoriatic arthritis enrollees saw 50% reduction in arthritis + 10%+ weight loss over 36 weeks (vs <1% Taltz alone)" |
| 2025-03 | [[2025-12-23-lifetime-social-returns-from-expanding-access-to-a]] | Research (COUNTER) | "Highest social returns from AOMs are for younger/healthier patients (BMI 30-39), NOT sickest; generic GLP-1 entry not until 2032 — high-cost period extends longer than bull case assumes" |
| 2025-08 | [[20aug25-robinhood-health-pitch-deck-c86df716]] | Research (COUNTER) | "Medicaid quality gaps massive: colorectal screening 39% vs 56% commercial, diabetes control 52% vs 71%; 72M Medicaid patients may not access GLP-1s — bifurcated adoption risk" |
| 2025-01 | [[2025-12-23-trumps-initial-orders-reverse-biden-on-health-care]] | News (COUNTER) | "Trump revoked Biden healthcare cost reduction EO; ACA expansion rolled back; federal hiring freeze at HHS — policy headwinds for GLP-1 Medicare coverage expansion" |

---

*Confidence: MEDIUM-HIGH — Adoption momentum is overwhelming (>7% of all prescriptions, oral launch, Medicare coverage). Channel disruption validated (HCA D2C, PBM transparency pressure). But persistence problem (14% at 3 years) and NBER cost-offset failure are material threats. If patients cycle on/off and costs never bend, the macro restructuring thesis weakens to a pharma-only story.*
*Last rebuilt: 2026-01-26*
